title: [Should we screen for prostate cancer?].
abstract: The controversy concerning the justification for prostatic cancer screening is now about ten years old. It is the consequence of several convergent phenomena: the routine use of new diagnostic tools such as prostate specific antigen, ageing of Western populations, increased life expectancy and finally public health economic aspects. Is screening justified before the age of 50 years? The answer is no, except in high-risk families with several cases of prostatic cancer, in which screening should be started at the age of 40 years. Is screening justified after the age of 70 years? The answer is no, except in men between 70 and 75 years whose general state and physiological age suggest that they have a life expectancy exceeding ten years. Is screening justified between 50 and 70 years? There is no global "medico-economic" answer to this question, as medical truth, i.e. the individual's interests, appears to be diametrically opposed to economic truth, i.e. the community's interests, due to the high cost of screening. How can screening be envisaged for the future? In families with no particular risk, screening should be clinical, but will probably start earlier and will continue later, because of the improvement of diagnostic tools and prolongation of life expectancy. In high-risk families, the development of genetic tests will be able to determine whether or not a man has inherited predisposition genes. If he has inherited these genes, he will then be submitted to particularly early, meticulous and repeated screening.
authors.affiliation: Service d'Urologie, CHU Nancy-Brabois.
authors.forename: P
authors.initials: P
authors.lastname: Mangin
authors.forename: L
authors.initials: L
authors.lastname: Cormier
authors.forename: A
authors.initials: A
authors.lastname: Valéri
mesh_terms: D000367:Age Factors; D000368:Aged; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods*; D008875:Middle Aged; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000517:prevention & control*
vernacular_title: Faut-il dépister le cancer de prostate?